Comparative Docking Studies of Aristolochic Acid B Against Lung Cancer Protein PTEN

Author(s): R. Girija, S. Aruna and R. Sangeetha

Abstract: Aristolochia bracteolate (A. bracteolate) is a main subdivision in the family of Aristolochiaceae. A.bracteolata is commonly called “worm killer”. A.bracteolate is used in conventional medicine for gastric stimulant, tumor, lung cancer, diarrhea, and snakebites. Lung inflammation or lung tumor is a major reason death for similar to both male and female. SCLC is a threatening neoplasm, for ~25-30% of all lung cancer patients. Molecular mechanisms (MM) adapt in SCLC incorporate induced utterance of oncogene, and loss of cancer defeat genes such as PTEN Tumor Suppressor Protein. The overexpression of PTEN proteins in SCLC is mostly effect of gene amplification. These over expression leads to swift proliferation and loss of terminal distinction. Alteration or deletion of PTEN canister lead to more swift proliferation and minimized apoptosis. The potential ligand candidate was identified from Pubchem database. A. bracteolata is derived compounds such as Aristolochic acid A, Aristolochic acid B, Aristolochic acid C, Aristolochic acid D and Aristolochic acid E. Lipinski rule was employed to check the ligand likeliness of the compound. The 3D crystallographic structure of PTEN Tumor Suppressor Protein (ID.1D5R) fetched from the PDB (Protein Data Bank) and protein target sites of the ligands were identified. Comparative docking studies was executed using Schrodinger Maestro 11.9. Hence it has been concluded Aristolochic acid B as a potent inhibitor for Lung cancer.

PAGES: 615-621  |  150 VIEWS  305 DOWNLOADS